Of the blockbusters in fiscal 2025, 35 products involved Japanese companies. Ono Pharmaceutical’s Opdivo had the highest sales, followed by Xtandi and Entyvio. Globally, Kerendia and Alyftrek are cited as new blockbuster candidates for fiscal 2026.
Of the blockbusters in fiscal 2025, 35 products are reported to have involved Japanese companies. Ono Pharmaceutical’s Opdivo had the highest sales among the products covered, followed by Xtandi and Entyvio, the same top-ranked products as in the previous fiscal year.
In terms of trends in the global market, Kerendia and Alyftrek are cited as new blockbuster candidates for fiscal 2026. The article is a feature available only to paid members, and further details must be checked separately.
The article positions Opdivo as the highest-revenue product among the fiscal 2025 blockbusters involving Japanese companies, and presents the global outlook for fiscal 2026 together with the overall composition of products involving Japanese companies.
The global market outlook highlights Kerendia and Alyftrek as potential future blockbuster candidates. The article’s gist is to present the current status of products related to Japanese companies and future candidates.